Elysium Health

Elysium Health™ Announces the Launch of MOSAIC™ for Skin Aging

Retrieved on: 
Wednesday, October 4, 2023
Elasticity, Partnership, Elysium Health, Skin care, Health, Ageing, Hyaluronic acid, Research, MIT, Science, Sunlight, Oxidative stress, Novartis, Reactive oxygen species, Weill Cornell Medicine, Collagen, Longevity, Human, Skin, Carotenoid, Cosmetics, Elysium, Dermatology, Mosaic, Biology

NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the launch of MOSAIC™, a novel, clinically proven daily softgel for skin aging that strengthens and protects the skin from the inside-out. With the advisement and consultation of Dr. Richard Granstein, chair of the Department of Dermatology at Weill Cornell Medicine for nearly 30 years, Elysium Health purpose-built Mosaic with a foundation in advanced longevity science. Working throughout the layers of the skin, Mosaic leverages the rapidly growing body of research around a class of phytonutrients known as carotenoids, which combat both internal and external stressors that drive skin aging. Its novel formulation combines carotenoids with other synergistic phytonutrients and hyaluronic acid to create a foundation for optimal skin health–improving its resilience against stressors, increasing whole-body moisture, and reducing visible signs of photoaging.

Key Points: 
  • NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the launch of MOSAIC™, a novel, clinically proven daily softgel for skin aging that strengthens and protects the skin from the inside-out.
  • Working throughout the layers of the skin, Mosaic leverages the rapidly growing body of research around a class of phytonutrients known as carotenoids, which combat both internal and external stressors that drive skin aging.
  • In a single daily softgel, Mosaic takes a whole-body approach to skin care, providing a foundation to target intrinsic and extrinsic skin aging and combating it throughout the layers of the skin.
  • Dr. Richard Granstein is a member of the Elysium Health Scientific Advisory Board and holds equity in Elysium Health.

A Letter from the ChromaDex Chief Executive Officer

Retrieved on: 
Tuesday, February 21, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Elysium, United States Court of Appeals for the Federal Circuit, DNA, ChromaDex, Attention, Elysium Health, Patent, NR, Intellectual property, Nature, IP

Two of ChromaDex’s recently granted patents protect methods of making NR and various salt forms.

Key Points: 
  • Two of ChromaDex’s recently granted patents protect methods of making NR and various salt forms.
  • NRMCl and NRTare important intermediates in the production of the final ingredient NR Chloride (“NRCl”).
  • In addition, W.R. Grace has two crystal forms patented for NRCl and supplies NR exclusively to ChromaDex.
  • But the protective moat that surrounds the Chromadex Niagen® business is not solely based on intellectual property.

Elysium Health™ Announces Addition of Nine Systems to Leading Biological Age Test INDEX™ Alongside Launch of Aging Research Center by Elysium Health™

Retrieved on: 
Wednesday, February 15, 2023
Elysium, Happiness, Woman, Elysium Health, Health, Fertility, Diet, Blood, MIT, Epidemiology, Sleep, Nursing, Nurses' Health Study, Harvard University, Liver, Harvard T.H. Chan School of Public Health, Coronavirus Scientific Advisory Board, Inflammation, Research, Male, Female, INDEX, Heart, Disease, Loneliness, Public health, Machine learning, Cardiovascular disease, AI, Cancer, Kidney, Longevity, Pharmaceutical industry, Ageing, Index, List of Nature Research journals

NEW YORK, Feb. 15, 2023 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging, today announced the addition of nine new measures of aging to its leading biological age test INDEX™ alongside the launch of the Aging Research Center by Elysium Health, both of which are firsts in the longevity field. Already the most precise biological age test available compared to other published epigenetic measures of aging, and utilizing superior technology demonstrated in Nature Aging, Index now measures the ages of nine systems–brain, liver, metabolic, immune, heart, hormone, kidney, inflammation, and blood. Elysium Health is pleased to be the first company to offer this level of novel in-depth insight.

Key Points: 
  • NEW YORK, Feb. 15, 2023 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging, today announced the addition of nine new measures of aging to its leading biological age test INDEX ™ alongside the launch of the Aging Research Center by Elysium Health, both of which are firsts in the longevity field.
  • The study of epigenetics is at the forefront of research in the field of aging, and biological age is becoming a leading standard to measure overall health and wellness.
  • Through collaboration with the Elysium community, the Aging Research Center will provide consumers with the first-ever opportunity to participate directly in longevity research, enabling greater public access to breakthroughs in the field.
  • The Aging Research Center will debut with a landmark prospective aging study–the Translational Initiative to Map Epigenetics in Aging (TIME-A).

Acute Kidney Injury Market to Grow at a CAGR of Approximately 8% by 2032 | DelveInsight

Retrieved on: 
Tuesday, June 21, 2022
Elysium, Character, Population, Sepsis, Vomiting, Astellas Pharma, ARF, Pharmed Group, Dizziness, Diuretic, Oliguria, Acute kidney injury, Nitrogen, Renal replacement therapy, RRT, Quark Pharmaceuticals, Disease, Urine, Weakness, AKI, Kidney failure, Azotemia, SCR, LAS, ACE, ARBS, Patient, United Kingdom, Elysium Health, Diagnosis, Awareness, LG Chem, Nausea, C1-inhibitor, Nonsteroidal anti-inflammatory drug, Pharmaceutical industry, Dietary supplement

LAS VEGAS, June 21, 2022 /PRNewswire/ -- DelveInsight's Acute Kidney Injury Market Insights report includes a comprehensive understanding of current treatment practices, Acute Kidney Injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan. 

Key Points: 
  • As per DelveInsight analysis, the Acute Kidney Injury market size in the 7MM was approximately USD 5.4 billion in 2020.
  • As per DelveInsight analysis, the total Acute Kidney Injury incident cases in the 7MM were approximately 10.9 million in 2020.
  • The key driver for the surge in acute kidney injury market size is the rise in the number of incident cases of acute kidney injury.
  • To know more about Acute Kidney Injury treatment, visit @ Acute Kidney Injury Guidelines

Elysium Health™ Announces Research at Mayo Clinic to Study Associations Between NAD+ Levels and Senescent Cell Burden and Develop Epigenetic Measures of Cellular Senescence

Retrieved on: 
Wednesday, June 1, 2022
Elysium, Science, Human, Cellular senescence, Biomarker, NAD, Coronavirus, NADH, Genome, Biology, Research, Cell, Yale University, Ageing, Physical medicine and rehabilitation, Multimedia, DNA methylation, Metabolism, MIT, Growth, Elysium Health, Mortality, Disease, DNA, Health, ATP, Decision-making, Mayo Clinic, APEX, Skin, Sirtuin, Mobile phone, Medical imaging, Index

NEW YORK, June 1, 2022 /PRNewswire/ -- Elysium Health, Inc., a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.

Key Points: 
  • NEW YORK, June 1, 2022 /PRNewswire/ -- Elysium Health, Inc., a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.
  • Currently, there are no widely-available, accurate measures of cellular senescence to evaluate efficacy of senolytic compounds that are designed to clear senescent cells.
  • This research collaboration will explore the relationship between NAD+ levels and cellular senescence, and aim to identify a signal from which to develop novel epigenetic measures of cellular senescence and subsequently commercialize them.
  • Recent work in Dr. LeBrasseur's lab at Mayo Clinic has focused on cellular senescence and the impact of senescent cells on physical function, metabolism, and resilience.

Elysium Health™ Announces New Research Initiative in Partnership With the University of Oxford in Connection With the Landmark INTERBIO-21st Study

Retrieved on: 
Wednesday, April 6, 2022
Elysium, Risk, Life, Global Health, Fetus, Partnership, DNA, NEW, University, Growth, Multimedia, Parent, Caregiver, Reproductive medicine, Mother, APEX, Research, Pregnancy, Nuffield Department of Population Health, DNA methylation, Health, Elysium Health, Nature Medicine, Dissection, Reproductive health, Ageing, Century, Science, Genetics, IP, Pharmaceutical industry, Medical imaging, Cancer

NEW YORK, April 6, 2022 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging research, has entered into a material transfer agreement with the University of Oxford to analyze the DNA methylation patterns of 2,500 umbilical cord blood samples from the landmark INTERBIO-21st Study with the aim of developing novel, non-invasive, and accessible measures to help assess the risk of growth and neurodevelopment delay in early childhood. The research collaboration expands on Elysium Health's ongoing partnership with the University of Oxford, which includes the Oxford-Elysium Prize Fellowship in Cellular Health, exclusive licensing of IP, and other research partnerships.

Key Points: 
  • The research collaboration expands on Elysium Health's ongoing partnership with the University of Oxford, which includes the Oxford-Elysium Prize Fellowship in Cellular Health, exclusive licensing of IP, and other research partnerships.
  • In addition to a focus on aging, a cornerstone of Elysium Health is accessibility.
  • For Elysium Health, this is a significant advancement, as it expands on the company's research in women's health, and marks our first efforts in the field of children's health."
  • The Nuffield Department of Women's & Reproductive Health at the University of Oxford encompasses multidisciplinary research across four overarching themes; Cancer,Global Health,Maternal & Fetal Health and Reproductive Medicine & Genetics.

Elysium Health™ Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health

Retrieved on: 
Wednesday, March 23, 2022
Elysium, Dementia, Vascular dementia, Metabolism, Plasma, Blood pressure, Muscle atrophy, DNA, University, Risk, Growth, University of Oxford, Memory, Clinical trial, Patient, Caregiver, China–Cornell–Oxford Project, Pharmacology, Multimedia, APEX, Atrophy, Research, DNA methylation, Health, Elysium Health, Learning, Homocysteine, Brain, Science, MTA, Awareness, MRI, Disease, Partnership, Medical imaging, Index, Alzheimer's disease, Ageing

"At Elysium Health, we develop novel products based on advancements in aging research to support lifelong human health," said Elysium Health CEO Eric Marcotulli.

Key Points: 
  • "At Elysium Health, we develop novel products based on advancements in aging research to support lifelong human health," said Elysium Health CEO Eric Marcotulli.
  • The formulation of Elysium Health's long-term brain health product Matter, which was developed in partnership with the University of Oxford, is the result of the findings of the VITACOG study.
  • Furthermore, it offers the potential to assess brain health quickly and easily, without the need for multiple brain scans."
  • Elysium Health will seek to identify a whole brain health signal as well as brain health signals for specific regions.

Elysium Health™ Announces Summary Judgment Decision in Case Against ChromaDex in New York--All of ChromaDex's Claims Against Elysium Health Dismissed

Retrieved on: 
Tuesday, February 15, 2022
Health, Elysium Health, Dartmouth College, Science, District, United States district court, Douglas v. U.S. District Court ex rel Talk America, Central District, ChromaDex, Ageing, Patent, Research, District court, Online gambling, Tobacco, Elysium

What remains in the New York case are several claims, including one for which the judge has already found that ChromaDex made false statements about Elysium Health's product Basis.

Key Points: 
  • What remains in the New York case are several claims, including one for which the judge has already found that ChromaDex made false statements about Elysium Health's product Basis.
  • "Elysium Health has maintained for years that ChromaDex's legal accusations were without merit," said Elysium Health CEO Eric Marcotulli.
  • Elysium Health is gratified that the judge has thus far ruled in the company's favor, and looks forward to a successful conclusion of this case.
  • Elysium Health's mission is to solve the biggest challenges in health with science, to help people lead healthier lives.

Elysium Health™ Announces the Launch of SIGNAL™ for Metabolic Aging

Retrieved on: 
Tuesday, January 25, 2022
Elysium, Research, Imai, NAD, Ageing, Sport, Sirtuin 3, Mitochondrion, Overalls, Das, Elysium Health, International Society, Liao, Enzyme, Science, ATP, VO2, Biology, Metabolism, Health, Animal, SIGNAL, Tissue, Sirtuin, Fasting, NMN, Efficiency, Nicotinamide mononucleotide, ALS, Environment, MIT, Multimedia, Life, Cell, Calorie, Partnership, Amyotrophic lateral sclerosis, Pharmaceutical industry, Signal, SIRT3

"At Elysium Health, we recognize that aging is a multi-factor problem that requires a multi-factor solution," said Elysium Health CEO Eric Marcotulli.

Key Points: 
  • "At Elysium Health, we recognize that aging is a multi-factor problem that requires a multi-factor solution," said Elysium Health CEO Eric Marcotulli.
  • "With each new product we get closer to addressing aging holistically, and to offering our customers the opportunity to truly personalize their Elysium Health regimen.
  • The launch of Signal marks the fifth consumer product for Elysium Health since the brand launched in early 2015.
  • Working directly with the world's leading scientists and clinicians, Elysium Health is committed to translating critical advancements in aging research into health solutions people can access today.

Elysium Health™ Announces the Launch of FORMAT™ Advanced Immune Support

Retrieved on: 
Wednesday, October 6, 2021
Elysium, Sleep, Research, Immunosenescence, National, MIT, Biology, FORMAT, Inflammation, Health, Ageing, Elysium Health, Multimedia, Chalcone, Vegetable, Immune system, Micronutrient, Antioxidant, Quercetin, Science, Diet, Mayo Clinic, Smoking, Anxiety, Saeid Yousefzadeh, Education, Disorder, Vaccine, Pharmaceutical industry

NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Elysium Health, Inc., a leading life sciences company developing clinically validated health products based on advancements in aging research, today announced the launch of FORMAT, the first and only immune product to uniquely pair a daily immunomodulatory supplement with an intermittent senolytic complex to combat the effects of immune aging and provide complete immune support.

Key Points: 
  • NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Elysium Health, Inc., a leading life sciences company developing clinically validated health products based on advancements in aging research, today announced the launch of FORMAT, the first and only immune product to uniquely pair a daily immunomodulatory supplement with an intermittent senolytic complex to combat the effects of immune aging and provide complete immune support.
  • "At Elysium Health, we develop novel products with the world's best scientists and institutions at the forefront of aging research to help people lead healthier lives," said Elysium Health CEO Eric Marcotulli.
  • Format is the first and only product to address immune aging by uniquely combining a daily immune supplement to support healthy immune function with an intermittent senolytic complex to help the body manage senescent cells and combat inflammaging and immunosenescence."
  • "It is a safe way to provide multi-pronged immune support that is not available in any other health supplement.